What is the recommended curative multimodal treatment approach for an aggressively invasive esophageal carcinoma in a medically fit patient?

Aggressive Invasive Oesophageal Cancer: Curative Multimodal Treatment

For aggressive invasive oesophageal cancer in a medically fit patient, the treatment approach depends critically on histology: squamous cell carcinoma (SCC) should receive neoadjuvant chemoradiotherapy followed by surgery (trimodality), while adenocarcinoma (AC) can receive either neoadjuvant chemoradiotherapy or perioperative chemotherapy, both followed by surgery. 1, 2

Treatment Algorithm by Histology

For Squamous Cell Carcinoma (SCC)

Primary recommendation: Neoadjuvant chemoradiotherapy followed by surgery 1

• Regimen: Weekly carboplatin-paclitaxel with radiation 41.4 Gy in 23 fractions (CROSS protocol), followed by oesophagectomy 1
• This achieves 5-year overall survival >60% for SCC, substantially higher than surgery alone or definitive CRT 1
• Alternative option: Definitive CRT (50.4 Gy in 28 fractions with cisplatin-5FU) with close surveillance and salvage surgery for local progression 1
  • This approach shows equivalent overall survival to trimodality in some trials, though with higher local recurrence rates 1
  • Particularly appropriate for cervical tumours where surgery would require laryngectomy 1

For Adenocarcinoma (AC)

Two evidence-based options exist 1, 2:

1. Neoadjuvant chemoradiotherapy (CROSS protocol: carboplatin-paclitaxel + 41.4 Gy) followed by surgery 1
2. Perioperative chemotherapy (FLOT regimen preferred based on recent head-to-head comparisons showing superior overall survival) 3

Both approaches are Class I evidence and superior to surgery alone 2, 3. Recent data suggest FLOT perioperative chemotherapy may have a survival advantage 3.

Surgical Approach

Minimally invasive oesophagectomy (MIO) is the preferred surgical technique in experienced centres 1:

• Lower post-operative morbidity, quicker functional recovery, and better quality of life up to 1 year compared to open surgery 1
• Oncological outcomes (resection margins, lymph node yield, survival) are at least non-inferior to open surgery 1
• Recent population-based data show better long-term overall survival with MIO 1

Specific procedures:

• Distal tumours: Ivor Lewis procedure (abdominal and right chest access, gastric tube conduit with anastomosis in upper mediastinum) 1
• Mid/upper tumours: McKeown procedure (abdominal, right chest, and cervical access with cervical anastomosis) 1
• Radical transthoracic oesophagectomy with en bloc two-field lymphadenectomy is standard 1

Critical Implementation Points

Radiation Dose Considerations

• Do not exceed 50.4 Gy in neoadjuvant setting 1
• Doses >55 Gy are associated with increased post-operative mortality and morbidity if salvage surgery is considered 1
• Randomised trials show no improved local control or survival with doses >50.4 Gy 1

Emerging Adjuvant Therapy

For patients who undergo neoadjuvant CRT followed by surgery with residual disease, adjuvant nivolumab is now recommended (hazard ratio for death 0.69; P < 0.001) 1. PD-L1 testing is not required for this indication 1.

Common Pitfalls to Avoid

1. Do not perform surgery alone for locally advanced disease (cT2-T4a or cN+) - multimodality therapy is mandatory 1, 2
2. Do not use excessive radiation doses (>50.4 Gy) in neoadjuvant setting - increases surgical complications without survival benefit 1
3. Do not perform palliative resections - use interventional procedures for palliation instead 4
4. Distinguish histology carefully - SCC and AC require different treatment paradigms due to differing radiosensitivity 1, 2

Mandatory Prerequisite

Multidisciplinary team assessment and planning before any treatment is mandatory 1. This is a Level IV, Grade A recommendation that cannot be bypassed.